Understand the source comparison
LL-37 vs BPC-157 & TB-500 — Wound Healing Context
BPC-157 and TB-500 dominate wound healing research because they accelerate the cellular processes that close tissue defects: angiogenesis, fibroblast proliferation, collagen deposition, and keratinocyte migration. BPC-157, a synthetic pentadecapeptide derived
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157 and TB-500 dominate wound healing research because they accelerate the cellular processes that close tissue defects: angiogenesis, fibroblast proliferation, collagen deposition, and keratinocyte migration. BPC-157, a synthetic pentadecapeptide derived from gastric BPC protein, upregulates VEGF and stabilizes nitric oxide production to enhance blood vessel formation in ischemic tissue. TB-500 (thymosin beta-4) promotes actin polymerization and cell motility, allowing fibroblasts and endothelial cells to migrate into wound beds faster than baseline healing would permit. Both peptides consistently reduce wound closure time by 30–50% in animal models compared to untreated controls.
- What they don't do is address bacterial colonization or biofilm formation. Factors that dramatically slow wound healing in clinical and research contexts. A wound contaminated with Staphylococcus aureus or Pseudomonas aeruginosa won't close efficiently no matter how much angiogenic signaling BPC-157 provides, because the inflammatory burden from active infection overwhelms the regenerative response. LL-37 disrupts bacterial membranes and prevents biofilm adhesion to the wound surface, creating a microenvironment where BPC-157 and TB-500 can function as intended. Research in Wound Repair and Regeneration (2018) demonstrated this synergy: wounds treated with TB-500 alone closed in 14 days, while wounds treated with TB-500 plus LL-37 closed in 9 days when bacterial load was present. The antimicrobial function removed the rate-limiting factor.
- For sterile wound models or in vitro studies where infection isn't a variable, BPC-157 and TB-500 are sufficient. For any model involving mucosal surfaces, diabetic tissue, compromised immune function, or environmental contamination, LL-37 becomes the functional prerequisite that allows other peptides to work.